abstract |
The invention features methods of inhibiting activation of cells by viral erb-B ligands and methods of enhancing immune responses in animals (e.g., human subjects) infected, that will be infected, or are at risk of being infected with a virus whose genome contains a nucleic acid sequence encoding a viral erb-B ligand. |